In a major victory for public health, Congress passed the Mainstreaming Addiction Treatment Act (MAT Act) at the end of 2022.

What does this mean for you as a Healthcare Provider?
Prescribing buprenorphine for opioid use disorder just got easier. The DATA-Waiver (X-Waiver) Program was eliminated on December 29, 2022, with President Biden’s signing of the Consolidated Appropriations Act of 2023, which contains the Mainstreaming Addiction Treatment Act (MAT Act). Now, practitioners with a current Drug Enforcement Administration (DEA) registration may prescribe buprenorphine for opioid use disorder if permitted by state law.

New Training Requirements Issued for DEA Registration
New training requirements for DEA registration were also introduced in the Omnibus bill, but will not go into effect until June 21, 2023. The requirements are summarized as at least 8 hours of training on the treatment and management of patients with opioid use disorder. The DEA and SAMHSA will provide further guidance on these requirements in the coming months.

Resources to Help Spread the Word
- Check out our victory video at: ppls.ac/MATActVictoryVid
- Share this one-pager: ppls.ac/MATActHCP
- Share our community-focused one-pager: ppls.ac/MATActComm
- Review the Substance Abuse and Mental Health Services Administration’s official announcement about this change: ppls.ac/MATActSAMHSA